J.P. Morgan Highlights: Medtech Company Updates For 2022
CEOs Present At J.P. Morgan's Annual Healthcare Conference
The annual J.P. Morgan Healthcare Conference saw major medtech companies describe their experiences in 2021 and expectations for 2022 as they continue to cope with COVID-19.
You may also be interested in...
Strategics pursuing high growth M&A plays are often ready to pay a premium price for a target. But with medtech valuations at historic highs, they cannot afford to do that every time. One solution is to take a strategic stake and build early, according to an AdvaMed panel hosted by EY’s John Babitt.
Joaquin Duato has been involved for the last several years in growing J&J’s pharma and consumer businesses and has led the company’s COVID-19 efforts. Alex Gorsky is stepping down due to a family health issue.
Edwards Lifesciences reported $1.2bn in sales in the first quarter of 2021, up 5% year-over-year and exceeding the projections the company offered three months ago.